In another study, Mitchell et al. demonstrated that upon prevention of mTOR signaling with the dual PI3K/mTOR inhibitors PI-103 or NVP-BEZ235, autophagy became elevated in CML and ponatinib-resistant leukemic cells and in turn effectively sensitized these cells to HCQ treatment [145]. The gene discussed is MTOR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.